A Phase 2, Randomized Study of Bortezomib/Dexamethasone With or Without Elotuzumab in Subjects With Relapsed/Refractory Multiple Myeloma.

Trial Profile

A Phase 2, Randomized Study of Bortezomib/Dexamethasone With or Without Elotuzumab in Subjects With Relapsed/Refractory Multiple Myeloma.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Jun 2016

At a glance

  • Drugs Elotuzumab (Primary) ; Bortezomib; Dexamethasone; Dexamethasone
  • Indications Multiple myeloma
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Jun 2016 This trial was Completed in Spain, according to the European Clinical Trials Database.
    • 16 May 2016 Planned End Date changed from 1 Apr 2016 to 1 Aug 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top